Phase 1 of the study is intended to test the safety of three dose levels of the new vaccine — mRNA-1273 — named after the genetic material that makes up the injections and which researchers say can produce a vaccine very quickly.
“This study is the first step in the clinical development of an mRNA vaccine” against coronavirus, said Dr. Tal Zaks, chief medical officer at Moderna, in a statement.
The trial will include 45 healthy adults ages 18 to 55. Each participant will receive two shots, 28 days apart. Three different doses will be tested on 15 people each and the participants will be studied to determine whether the vaccine is safe.
IRAN - Data point
Zali also acknowledged that “many” of those who have died from the COVID-19 illness caused by the virus were otherwise healthy, a rare admission by local authorities that the virus does not only prey on the sick and elderly.
Health Ministry figures show that while 55 percent of fatalities were in their 60s, some 15 percent were younger than 40.
https://www.foxnews.com/world/iran-coronavirus-deaths-jump
Moderna is in bed with gates.
gates can’t open his mouth without bemoaning the presence of other humans on his planet.